Loading clinical trials...
Loading clinical trials...
Imagery Rescripting and Imaginal Exposure for Anxiety Symptoms: Mechanisms and Outcomes in a Large Analog Sample
This study will recruit 460 participants who self-report high symptoms of anxiety. Participants will be randomly assigned to one of 4 groups: one analog intervention of Imagery Rescripting (IR) for memories, an analog intervention of IR for future events, and analog intervention of Imaginal Exposure (IE) for memories and an analog intervention of IE for future events. We will examine the efficacy and mechanisms behind each intervention.
After being informed about the study potential risks, all patients giving written informed consent will undergo screening to determine eligibility for study entry. They will be randomly assigned to one of four conditions (Imagery rescripting past; Imagery rescripting future; Imaginal exposure past; Imaginal exposure future) at a 1:1:1:1 ratio (n = 115 per group). Participant will be assigned using a variance minimization method that controls for between group variance in continuous and categorical variables- SPIN, ASI-3, OCI-R, GAD-7 and gender with a completely random assignment p random = .2 (for algorithm see Sella et al., 2018). Participants will attend three \~1.5 hour online ZOOM sessions (baseline-assessment and measurement, intervention, post assessment and measurement and follow-up measurement). In this multiple baseline study, participant will enter the intervention phase either 7 or 14 days after the baseline stage. Assessors will be blind to the treatment condition.
Age
18 - 70 years
Sex
ALL
Healthy Volunteers
Yes
Hebrew University of Jerusalem
Jerusalem, Israel
Start Date
April 14, 2022
Primary Completion Date
January 1, 2025
Completion Date
January 1, 2025
Last Updated
October 26, 2022
460
ESTIMATED participants
Imaginal exposure for memories
BEHAVIORAL
Imaginal exposure for future events
BEHAVIORAL
Imagery rescripting for memories
BEHAVIORAL
Imagery rescripting for future events
BEHAVIORAL
Lead Sponsor
Hebrew University of Jerusalem
NCT07456631
NCT07429578
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions